ArticleClinical and translational medicine2020
Improving transgene expression and CRISPR-Cas9 efficiency with molecular engineering-based molecules.
Article in Clinical and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Expanding the CRISPR/Cas toolkit: applications in proteomics and theranostics.Frontiers in bioengineering and biotechnology · 2025Review
- CRISPR-based gene expression platform for precise regulation of bladder cancer.Cellular & molecular biology letters · 2024Article
- Exosome-mediated delivery of artificial circular RNAs for gene therapy of bladder cancer.Journal of Cancer · 2024Article
- An Update of Nucleic Acids Aptamers Theranostic Integration with CRISPR/Cas Technology.Molecules (Basel, Switzerland) · 2022Review
- Deletion and replacement of long genomic sequences using prime editing.Nature biotechnology · 2022Article
- Discovery in clinical and translational medicine.Clinical and translational medicine · 2021Article
- Potential biomarkers and targets of mitochondrial dynamics.Clinical and translational medicine · 2021Review
- Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors.Pharmaceuticals (Basel, Switzerland) · 2021Review
- CORRIGENDUM.Clinical and translational medicine · 2021Article
- Improving transgene expression and CRISPR-Cas9 efficiency with molecular engineering-based molecules.Clinical and translational medicine · 2020Article
Corrections and comments
- Erratum issuedCORRIGENDUM.2021
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
As a novel and robust gene-editing tool, the Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 (CRISPR-Cas9) system has revolutionized gene therapy. Plasmid vector delivery is the most commonly used method for integrating the CRISPR-Cas9 system into cells. However, such foreign cytosolic DNAs trigger an innate immune response (IIR) within cells, which can hinder gene editing by inhibiting transgene expression. Although some small molecules have been shown to avoid the action of IIR on plasmids, they only work on a single target and may also affect cell viability. A genetic approach that works at a comprehensive level for manipulating IIR is still lacking. Here, we designed and constructed several artificial nucleic acid molecules (ANAMs), which are combinations of aptamers binding to two key players of IIR (β-catenin and NF-κB). ANAMs strongly inhibited the IIR in cells, thus improving transgene expression. We also used ANAMs to improve the gene-editing efficiency of the CRISPR-Cas9 system and its derivatives, thus enhancing the apoptosis of cancer cells induced by CRISPR-Cas9. ANAMs can be valuable tools for improving transgene expression and gene editing in mammalian cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.